	US 12,146,139 B2
	Oligonucleotide interference treatments of prostate cancer
Maria Jesus Ruiz Echevarria, Edmond, OK (US); and Joshua Moses Corbin, Oklahoma City, OK (US)
Assigned to The Board of Regents of the University of Oklahoma, Norman, OK (US)
Appl. No. 17/441,895
Filed by The Board of Regents of the University of Oklahoma, Norman, OK (US)
PCT Filed Nov. 16, 2020, PCT No. PCT/US2020/060753 § 371(c)(1), (2) Date Sep. 22, 2021, PCT Pub. No. WO2021/097437, PCT Pub. Date May 20, 2021.
Claims priority of provisional application 62/935,521, filed on Nov. 14, 2019.
Prior Publication US 2022/0275374 A1, Sep. 1, 2022
Int. Cl. C12N 15/113 (2010.01); A61P 35/00 (2006.01)

CPC C12N 15/1138 (2013.01) [A61P 35/00 (2018.01); C12N 2310/11 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01)]

26 Claims

1. A nucleic acid compound, comprising

an oligonucleotide selected from the group consisting of short interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA, antisense DNA, Chimeric Antisense DNA/RNA, and microRNA (miRNA), wherein the oligonucleotide comprises the nucleic acid sequence SEQ ID NO:60, and nucleic acid sequences complementary to said sequence; and

wherein the nucleic acid compound comprises at least one of (1) a non-natural modification in the oligonucleotide, and (2) an organic moiety conjugated to the oligonucleotide, with the proviso that X₂, X₃, and X₄of SEQ ID NO:60 are selected from uracil and a modified uracil nucleobase, with the proviso that the modified uracil nucleobase is not a thymine; and wherein the nucleic acid compound has inhibitory activity against the expression or biological activity of an androgen receptor (AR) coregulator or biologically active fragment thereof.